ESG and Sustainability Advisory Market: A Strategic Imperative for Biotechnology and Life Sciences

As regulatory frameworks tighten and investor scrutiny intensifies, the ESG and sustainability advisory market is projected to approach $85.8 billion by 2035, with significant implications for the biotechnology and life sciences industries.

Executive Summary

The global ESG and sustainability advisory market was valued at approximately $47.1 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 6.19% through 2035, reaching nearly $85.8 billion, according to a market analysis by Global Growth Insights. This growth is underpinned by rising corporate accountability requirements, increased investor demand for transparent ESG reporting, and stronger regulatory frameworks worldwide. For the biotechnology sector, ESG advisory services are becoming essential tools for managing climate risk, demonstrating ethical governance, and aligning innovation with sustainable development goals. This article examines the market dynamics, industry implications, and the strategic role of sustainability advisory in shaping the future of life sciences.

Introduction

The biotechnology industry operates at the intersection of scientific innovation and societal impact. As companies develop next-generation therapies, sustainable agricultural solutions, and advanced diagnostics, they also face growing expectations to address environmental, social, and governance (ESG) factors. The ESG and sustainability advisory market has emerged as a critical enabler for organizations seeking to navigate this complex landscape. With more than 40% of enterprises now integrating ESG strategies into long-term planning, advisory services are no longer a compliance afterthought but a strategic imperative for risk management, capital access, and corporate resilience.

The market's trajectory is particularly relevant for biotechnology and life sciences, where research and development timelines are long, capital intensity is high, and public trust is essential. ESG advisory services help these organizations align with frameworks such as the Task Force on Climate-related Financial Disclosures (TCFD), the Global Reporting Initiative (GRI), and the International Sustainability Standards Board (ISSB), while also addressing sector-specific considerations like clinical trial ethics, supply chain transparency, and environmental impact of manufacturing processes.

Scientific Background: ESG Advisory and the Life Sciences Ecosystem

ESG and sustainability advisory services encompass a range of offerings, including materiality assessments, net-zero roadmap design, ESG ratings improvement, and stakeholder engagement strategies. In the context of biotechnology, these services are increasingly tailored to the unique challenges of the industry. For instance, biomanufacturing facilities are energy intensive, and the production of biologics often involves significant water use and waste generation. Advisory firms assist companies in developing decarbonization strategies, optimizing resource efficiency, and implementing circular economy models.

Moreover, the social component of ESG is particularly salient for life sciences. Issues such as equitable access to medicines, diversity in clinical trials, and ethical sourcing of biological materials are gaining prominence. ESG advisory firms help biotechnology companies develop governance structures that address these concerns, thereby enhancing their social license to operate and reducing regulatory and reputational risks.

The scientific and clinical aspects of biotechnology also intersect with sustainability. For example, the development of environmentally friendly reagents, the reduction of single-use plastics in laboratories, and the adoption of green chemistry principles are all areas where ESG advisory services can provide strategic guidance. This alignment between scientific innovation and sustainable practices is not only ethically sound but also increasingly demanded by investors and regulators.

Research Findings: Market Size, Growth, and Key Trends

According to the Global Growth Insights report, the global ESG and sustainability advisory market was valued at USD 47,059.1 million in 2025 and is expected to reach USD 49,972.1 million in 2026, USD 53,065.4 million in 2027, and approximately USD 85,798.5 million by 2035, reflecting a CAGR of 6.19% from 2026 to 2035. This steady growth is driven by several factors:

Regulatory Pressure: In the European Union, over 51,000 companies will be subject to mandatory ESG reporting under the Corporate Sustainability Reporting Directive (CSRD) from 2025. In the United States, the SEC's climate disclosure rule is prompting 48% of public firms to seek ESG advisory support. These regulatory shifts are spurring demand across all sectors, including biotechnology.
Investor Demand: Investors increasingly incorporate ESG metrics into their investment decisions. Over 68% of global corporations are enhancing ESG reporting, and ESG-linked financing is becoming a standard mechanism for raising capital. For biotechnology companies, robust ESG performance can lower cost of capital and attract impact-driven investors.
Strategic Integration: A significant trend is the integration of ESG into core business strategy, with 61% of listed companies globally incorporating ESG KPIs into executive compensation. This development signals a shift from compliance-driven reporting to value-driven sustainability management.
Technology Enablement: Around 36% of advisory firms now partner with ESG software platforms to offer real-time data monitoring, AI-powered risk detection, and automated reporting. These technological capabilities are particularly valuable for biotechnology companies with complex global supply chains and diverse R&D portfolios.

The report also highlights specific market dynamics, including the rising demand for net-zero and decarbonization strategy services. With 56% of Fortune 500 companies committed to net-zero targets, the need for expert guidance in emissions baselining, target setting, and decarbonization roadmaps is growing. In the biotechnology sector, this includes assessing the carbon footprint of laboratory operations, clinical trial logistics, and cold chain distribution.

Industry Impact: Implications for Biotechnology and Life Sciences

The expansion of the ESG and sustainability advisory market has profound implications for the biotechnology industry:

Risk Management and Compliance: As regulatory frameworks like CSRD and SEC climate disclosures take effect, biotechnology companies must ensure accurate and verifiable ESG reporting. Advisory firms play a crucial role in helping these organizations build the necessary data infrastructure and governance processes.
Capital Formation and Valuation: Sustainability considerations are increasingly influencing M&A deal valuations, with ESG due diligence growing by 29%. For biotechnology startups and established players alike, a strong ESG profile can enhance attractiveness to investors, strategic partners, and acquirers.
Supply Chain Resilience: With a 33% uptick in supply chain ESG risk evaluation, biotechnology companies are using advisory services to ensure ethical sourcing, human rights compliance, and circularity. This is particularly important for sourcing of raw materials like enzymes, mammalian cell lines, and specialized chemicals.
Reputational Leadership: Biotechnology is a highly scrutinized industry, with public perception shaped by debates over genetic engineering, animal testing, and drug pricing. Proactive ESG strategy can differentiate companies as responsible innovators, strengthening brand equity and stakeholder trust.
Innovation Ecosystem Alignment: The circular bioeconomy is emerging as a key area where ESG and biotechnology intersect. Advisory services help companies develop biomaterials, bioplastics, and bio-based chemicals that align with sustainability goals, opening new market opportunities.

Clinical and Regulatory Perspective

From a regulatory standpoint, ESG reporting is no longer optional. In addition to financial disclosures, regulators are demanding transparency on climate-related risks and social impact. For biotechnology companies, this extends to the ethical conduct of clinical research, patient safety, and post-market surveillance. ESG advisory services assist in aligning corporate governance with these regulatory expectations, ensuring that environmental and social considerations are embedded in clinical development strategies.

However, there are challenges. The report notes a lack of standardization in ESG metrics and frameworks, with 46% of companies reporting confusion in determining reporting priorities. This fragmentation is particularly acute in emerging markets, where only 29% of ESG disclosures align with recognized global standards. For global biotechnology companies operating across multiple jurisdictions, harmonizing ESG KPIs remains a significant hurdle.

Another critical challenge is the shortage of qualified ESG professionals with sector expertise. Only 34% of ESG advisory firms report having sector-specialized sustainability consultants. For the biotechnology industry, which requires an understanding of both scientific rigour and sustainability metrics, this talent gap is particularly pronounced. Advisory firms are increasingly building cross-disciplinary teams that combine environmental science, regulatory affairs, and business strategy.

Future Outlook: The Next 5–15 Years

Looking ahead, the ESG and sustainability advisory market is expected to continue its upward trajectory, driven by innovation, technology, and regulatory evolution. For the biotechnology and life sciences sectors, several developments are likely:

AI-Driven ESG Analytics: Artificial intelligence will play an increasingly important role in ESG data collection, predictive climate risk modeling, and automated compliance reporting. Advisory firms will leverage AI to provide real-time insights and scenario analysis, enabling biotechnology companies to make proactive sustainability decisions.
Innovative Biomanufacturing: The adoption of renewable energy, water recycling systems, and carbon capture technologies in biomanufacturing will require specialized advisory services. As the industry moves toward continuous manufacturing and digital twins, ESG considerations will be integrated into process design from the outset.
Biodiversity and Natural Capital: Beyond climate change, biodiversity loss is gaining attention as a material ESG issue. Biotechnology companies that depend on genetic resources and ecosystems will need to assess and disclose their impact on biodiversity, creating new opportunities for advisory firms with expertise in this area.
Sustainable Supply Chains: The circular bioeconomy will accelerate, with companies seeking to minimize waste and maximize resource efficiency. ESG advisory services will guide the development of closed-loop supply chains, from raw material sourcing to end-of-life product management.
Global Harmonization of Standards: While the current landscape of ESG frameworks is fragmented, efforts to consolidate standards are underway. The ISSB's global baseline for sustainability disclosures is expected to gain traction, simplifying reporting for multinational biotechnology companies and reducing compliance costs.

Conclusion

The ESG and sustainability advisory market is not merely a peripheral consulting segment; it has become a strategic enabler for the biotechnology industry's long-term resilience. As the market approaches $85.8 billion by 2035, the imperative for biotechnology companies to integrate ESG considerations into their business models has never been clearer. From regulatory compliance and capital formation to supply chain management and reputational leadership, ESG advisory services offer a comprehensive framework for navigating the complex interplay between scientific innovation and societal responsibility.

For biotechnology executives, researchers, investors, and policymakers, the message is clear: sustainability is no longer a separate initiative but a core component of value creation. The advisory market's growth reflects a broader recognition that the future of medicine, food, and industrial biotechnology must be built on foundations of transparency, environmental stewardship, and ethical governance. TheBioTechReview.com will continue to track these developments, providing evidence-based analysis of how ESG and sustainability advisory is transforming the life sciences landscape.

Key Takeaways

The global ESG and sustainability advisory market is projected to reach USD 85.8 billion by 2035, growing at a CAGR of 6.19% from 2026 to 2035.
Regulatory drivers, including the EU's CSRD and U.S. SEC climate disclosure rules, are compelling biotechnology companies to enhance ESG reporting and governance.
ESG advisory services are becoming integral to risk management, capital formation, supply chain resilience, and corporate reputation in the life sciences sector.
Challenges such as metric standardization and a shortage of specialized ESG professionals remain, but technological innovation and global harmonization efforts are expected to improve adaptability.
The biotechnology industry is uniquely positioned to benefit from ESG advisory expertise, particularly as sustainable biomanufacturing and the circular bioeconomy gain momentum.

SEO Keywords

ESG and sustainability advisory market
Biotechnology ESG trends
Sustainability advisory life sciences
ESG reporting biotech
Net-zero biotechnology
ESG investment pharmaceuticals
Climate risk assessment biomanufacturing
Circular bioeconomy consultancy
Regulatory ESG frameworks in life sciences

Sources

Global Growth Insights. (2025). ESG and Sustainability Advisory Market Size, Share, Growth, and Industry Analysis. Retrieved from https://www.globalgrowthinsights.com/market-reports/esg-and-sustainability-advisory-market-103238